Buy SNY under $35
Health Care: Drugs
Oncothyreon Inc. (ONTY: NASDAQ)
$8.40 0.39 | 4.87%
02/10/12 - 04:07 PM ET
834.55K / 769.10K
Vol / Avg. Vol:7.97 / 8.01
Open / Prev. Close:7.91 - 8.40
Today's Range:3.01 - 11.59
52 Wk Range:5.80%
Performance YTD:TheStreet Rating:
Portfolios with ONTY
- Portfolio NameUser Type
- UserBen-Amsterdam
- UserCoralview
- Contributor5 Stocks Under-$10 Setting ...
- Contributor13 Biotech Stocks Bought an...
- Contributor10 Most Shorted Stocks in B...
- Userrab 's
- Contributor11 Biotech Stocks Loved or ...
- ContributorHeavily Shorted Market Lead...
- Contributor10 Biotech Trades for Secon...
- Contributor8 Health Care Stocks With R...
Latest ONTY Headlines from TheStreet
- Biotech Stock Mailbag: Corcept Therapeutics, Reader Retorts 02.10.12 | 07:02 am
- More Biotech Lessons Learned From JPM 2012 01.13.12 | 06:01 am
- Nasdaq Stocks Posting Largest Percentage Decreases 01.05.12 | 06:01 pm
- Biotech Buyside Predictions for 2012 01.05.12 | 09:01 am
- Biotech Stock Mailbag: Most Important Events for 2012 12.23.11 | 06:12 am
- 10 Biotech Stock Predictions for 2012 12.20.11 | 11:12 am
- Biotech Stock Live Chat: 2012 Preview 12.15.11 | 11:12 am
- 5 Stocks Under $10 With Big Upside Potential 11.18.11 | 06:11 am
- The Biotech Stock 13F Review: What Hedge Funds Were Buying and Selling 11.16.11 | 08:11 am
- 10 Most Shorted Stocks in Biotech 10.04.11 | 09:10 am
Press Releases for ONTY
- Oncothyreon Announces Promotion Of Diana Hausman, M.D., To Chief Medical Officer - PR Newswire 01.05.12 | 04:01 pm
- Oncothyreon Files Investigational New Drug Application For ONT-10 - PR Newswire 12.20.11 | 08:12 am
- Oncothyreon To Present At Oppenheimer Healthcare Conference - PR Newswire 12.07.11 | 08:12 am
- Oncothyreon Presents Data From Phase 1/2 Trials Of PX-866 In Combination With Docetaxel And With Cetuximab At 2011 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics - PR Newswire 11.13.11 | 03:11 pm
- Oncothyreon To Present At Lazard Capital Markets Healthcare Conference - PR Newswire 11.08.11 | 08:11 am
- Oncothyreon Announces Third Quarter 2011 Financial Results Conference Call - PR Newswire 11.01.11 | 08:11 am
- Oncothyreon Advances To Phase 2 Portion Of Phase 1/2 Trial Of PX-866 In Combination With Docetaxel - PR Newswire 10.20.11 | 08:10 am
- Chris Henney Receives 2011 Hall Of Fame Award At Annual Biotech CEO Meeting At Laguna Beach - PR Newswire 10.17.11 | 12:10 pm
- Oncothyreon To Present At BioCentury NewsMakers In The Biotech Industry Conference - PR Newswire 10.17.11 | 08:10 am
- Oncothyreon Initiates Phase 2 Trial Of Its PI-3 Kinase Inhibitor PX-866 In Patients With Prostate Cancer - PR Newswire 09.12.11 | 08:09 am
Partner Headlines for ONTY
- Stocks To Watch Week Of Feb. 6 - Seeking Alpha 02.06.12 | 08:02 am
- Oncothyreon: $31 For Shares? Don't Believe The Hype - Seeking Alpha 11.28.11 | 09:11 am
- Merck KGaA Washes Hands off PD Drug - Analyst Blog - Zacks 10.24.11 | 10:10 am
- Merck KGaA, Ono Pharma Collaborate - Analyst Blog - Zacks 10.14.11 | 04:10 pm
- ImmunoCellular Therapeutics: The Biotechnology Moneyball - Seeking Alpha 10.06.11 | 08:10 am
- 6 Deeply Undervalued Biotech Stocks - Seeking Alpha 07.27.11 | 09:07 am
- Oncothyreon: Possible Pharma Blockbuster -Seeking Alpha - Benzinga 07.20.11 | 09:07 am
- Oncothyreon: Possible Pharma Blockbuster - Seeking Alpha 07.20.11 | 09:07 am
- Options Brief: Oncothyreon Inc. - Benzinga 06.24.11 | 01:06 pm
- Top Percentage Gainers and Losers as of 2pm 05/13/11 (ABIO, GFRE, DDS, APL, DF, VRML, DAR, SWSH, ONTY, GS, RMBS, LPHI, GGS, CA, NVDA, IMRS, MNTX, MPG, GTY) - Benzinga 05.13.11 | 02:05 pm
